The year 2025 has brought continuous challenges, including recent federal policy changes proposed by the new administration that deeply concern SCBA. These changes-such as freezes and delays in federal funding, halted grant reviews, and proposed reductions in both overall federal research funding and indirect cost allocations-have created a crisis in the U.S. biomedical research landscape. Further cuts to NIH and other federal science budgets only compound these challenges, threatening the stability and future of biomedical research in the United States.

Scientific progress and public health depend on sustained investment in research. Now more than ever, we must defend and strengthen the U.S. biomedical research ecosystem to maintain our leadership in science and medicine, before the damage becomes irreversible.

SCBA remains committed to promoting excellence in biomedical research, fostering collaboration among scientists, and advocating for policies that support innovation and discovery. We strongly urge policymakers to take immediate action to protect the integrity of federally funded biomedical research. This includes restoring and expanding funding for critical research agencies such as NIH and FDA to ensure continued scientific progress and innovation.

SCBA also encourages its members and the broader scientific community to engage with their state and federal representatives, voicing their concerns and advocating for policies that support biomedical research. Together, we can safeguard the future of scientific discovery and its vital contributions to public health.

Full Letter